anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a composition and method for treating or preventing hyperacute rejection.  <P>SOLUTION: The invention relates to mucin-immunoglobulin fusion polypeptides, methods for producing the same and methods for treating or preventing hyperacute rejection and more particularly the mucin part of the fusion polypeptides has been glycosylated by an alpha 1, 3-galactosyltransferase and a beta 1, 6 N-acetylglucosaminyltransferase. This is based on that carbohydrate epitope Galα1, 3Gal(αGal) may be specifically expressed in high density by different core sugar chains on the main chain of mucin type protein. Such the αGal epitope of high density causes increase of binding or removal (that is, adsorption) of anti-αGal compared with free sugars or brings about an αGal determinant combined with solid phase. Here, the polypeptide is called as αGal fusion polypeptide.  <P>COPYRIGHT: (C)2011,JPO&INPIT
After the completion of the 6-month waitlist period, the experimental video intervention will be provided. The intervention will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). The intervention offered after the waitlist period will follow video intervention 1 (experimental arm).
CYP2C8 and CYP3A Substrates

RETEVMO is a moderate CYP2C8 inhibitor and a weak CYP3A inhibitor. Concomitant use of RETEVMO with CYP2C8 and CYP3A substrates increases their plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of RETEVMO with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

Certain P-gp Substrates

RETEVMO is a P-gp inhibitor. Concomitant use of RETEVMO with P-gp substrates increases their plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of RETEVMO with P-gp substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp substrates provided in their approved product labeling.
Developmental dyslexia is characterized by difficulties in learning to read, affecting cognition and causing failure at school. Interventions for children with developmental dyslexia have focused on improving linguistic capabilities (phonics, orthographic and morphological instructions), but developmental dyslexia is accompanied by a wide variety of sensorimotor impairments. The goal of this study was to examine the effects of a proprioceptive intervention on reading performance and eye movement in children with developmental dyslexia. Nineteen children diagnosed with developmental dyslexia were randomly assigned to a regular Speech Therapy (ST) or to a Proprioceptive and Speech Intervention (PSI), in which they received both the usual speech therapy and a proprioceptive intervention aimed to correct their sensorimotor impairments (prism glasses, oral neurostimulation, insoles and breathing instructions). Silent reading performance and eye movements were measured pre- and post-intervention (after nine months). In the PSI group, reading performance improved and eye movements were smoother and faster, reaching values similar to those of children with typical reading performance. The recognition of written words also improved, indicating better lexical access. These results show that PSI might constitute a valuable tool for reading improvement children with developmental dyslexia.
Twenty-nine patients in the Thomas Jefferson University (TJU) Blood and Marrow Transplantation Program have been treated on the research protocol, A Two Step Approach To Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies from HLA Partially-Matched Related Donors (TJU 2 Step RIC, TJU IRB# 06U.328) as of July, 2010. While treatment on this protocol has resulted in durable responses for many older patients and younger, heavily pretreated patients with hematological malignancies, poor performance status at the time of transplant and morbidities related to cyclophosphamide (CY) administration in the regimen have contributed to decreased survival. In addition, disease relapse after hematopoietic stem cell transplantation (HSCT) has been a major cause of mortality for those patients with disease at the time of transplant.

The objective of this research is to improve patient outcomes after treatment on the TJU 2 Step RIC protocol by refining the approach based on outcomes observed in the initial trial. More thorough assessment of performance status prior to HSCT and the substitution of the alkylating agent Melphalan (MEL) for CY to decrease CY-related toxicity while strengthening the anti-leukemic intensity of the regimen for patients with poor-risk disease will be the major strategies used to increase the efficacy of the regimen. MEL has shown efficacy against myeloid malignancies when used in conditioning in RIC HSCT. Patients with AML and MDS were the most common group treated on the initial TJU 2 Step RIC trial and also comprise the largest patient group treated in the TJU Medical Oncology Program.
Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin 50 mg/m2, and is manifested by tinnitus and/or hearing loss in the high frequency range (4,000 to 8,000 Hz). The prevalence of hearing loss in children is particularly high and is estimated to be 40 to 60%. Decreased ability to hear normal conversational tones may occur. Deafness after the initial dose of cisplatin has been reported. Ototoxic effects may be more severe in children receiving cisplatin.

Hearing loss can be unilateral or bilateral and tends to become more frequent and severe with repeated cisplatin doses. It is unclear whether cisplatin-induced ototoxicity is reversible. Vestibular toxicity has also been reported. Ototoxic effects may be related to the peak plasma concentration of cisplatin. Ototoxicity can occur during treatment or be delayed. Audiometric monitoring should be performed prior to initiation of therapy, prior to each subsequent dose, and for several years post therapy.

The risk of ototoxicity may be increased by prior or simultaneous cranial irradiation, and may be more severe in patients less than 5 years of age, patients being treated with other ototoxic drugs (e.g., aminoglycosides and vancomycin), and in patients with renal impairment. 

Genetic factors (e.g. variants in the thiopurine S-methyltransferase [TPMT] gene) may contribute to cisplatin-induced ototoxicity; although this association has not been consistent across populations and study designs.
Autistic young adults with intellectual disabilities want to be autonomous but are less autonomous than other people. However, they can be autonomous with appropriate support. We wanted to learn how we can support autistic adults with intellectual disabilities to be more autonomous. We designed our study with help from five autistic community partners to make sure the research was relevant to autistic people and would improve their lives. We talked with eight autistic young adults with intellectual disabilities about autonomy. We defined "talk" as verbal language, as well as non-verbal cues such as body language, facial expressions, vocalizations, and laughter. We did art projects and played games while we talked. We met in small groups over multiple sessions. Our participants told us that being autonomous meant being able to be themselves. They told us three main ways to support their autonomy: (1) having choice and control, (2) being able to communicate in their own way, and (3) being in a safe environment. Families, support staff, and caregivers can use this information to help autistic young adults with intellectual disabilities to be autonomous.
Central pattern of fat distribution, especially fat accumulation within the intraabdominal cavity increases risks for cardiometabolic diseases. Portal hypothesis combined with a pathological remodeling in visceral fat is considered the major etiological factor explaining the independent contribution of visceral obesity to cardiometabolic diseases. Excessive remodeling in visceral fat during development of obesity leads to dysfunctions in the depot, characterized by hypertrophy and death of adipocytes, hypoxia, inflammation, and fibrosis. Dysfunctional visceral fat secretes elevated levels of fatty acids, glycerol, and proinflammatory and profibrotic cytokines into the portal vein directly impacting the liver, the central regulator of systemic metabolism. These metabolic and endocrine products induce ectopic fat accumulation, insulin resistance, inflammation, and fibrosis in the liver, which in turn causes or exacerbates systemic metabolic derangements. Elucidation of underlying mechanisms that lead to the pathological remodeling and higher degree of dysfunctions in visceral adipose tissue is therefore, critical for the development of therapeutics to prevent deleterious sequelae in obesity. We review depot differences in metabolic and endocrine properties and expendabilities as well as underlying mechanisms that contribute to the pathophysiological aspects of visceral adiposity in cardiometabolic diseases. We also discuss impacts of different weight loss interventions on visceral adiposity and cardiometabolic diseases.
The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.
Data mining of a dental image is described. In an example scenario, an aggregator service receives a dental image of a patient from a dental image provider. The dental image is processed with a machine learning (ML) anatomy dataset. An anatomy from the ML anatomy dataset is identified and matched to the dental image. The dental image is next matched and identified with a ML pathology and treatment dataset. A pathology and a treatment from the ML pathology and treatment dataset are matched to the dental image. Next, the dental image and the anatomy, the pathology, and the treatment associated with the dental image are inserted to a patient dataset associated with the patient. A cluster analysis of the patient dataset is performed with a cluster dataset to produce a correlated dental image information. The correlated dental image information is provided to a data mining entity and to compile a diagnostic aid for a user.
ETHNOPHARMACOLOGICAL RELEVANCE: Flos Chrysanthemi Indici (FCI), the flower of Chrysanthemum Indicum L., is a popular traditional Chinese medicine (TCM) for treatment of inflammatory diseases in China. FCI is also a functional food, and is widely used as herbal tea for clearing heat and detoxicating.
AIM OF THE STUDY: To explore quality control markers of FCI based on the optimal harvest period.
MATERIALS AND METHODS: First, UPLC-Q-TOF/MS based untargeted metabolomics was applied to explore the chemical profiles of FCIs collected at bud stages (BS), initial stages (IS), full bloom stages (FS) and eventual stages (ES) from eight cultivated regions in China. Subsequently, lipopolysaccharide (LPS)-induced RAW264.7 cell inflammatory model and carrageenan-induced rat paw edema model were used to confirm the anti-inflammatory effect of FCIs collected at IS/FS. Then, UPLC-PDA targeted metabolomics was used to quantitatively analyze 9 constituents with anti-inflammatory activity (7 flavonoids and 2 phenolic acids) changed significantly (VIP > 4) during flowering stages. Finally, ROC curves combined with PCA analysis based on the variation of 9 active constituents in FCIs from different flowering stages were applied to screen the quality markers of FCI.
RESULTS: FCIs at IS/FS had almost same chemical characteristics, but quite different from those at BS and ES. A total of 32 constituents in FCIs including flavonoids and phenolic acids were changed during flowering development. Most of the varied constituents had the highest or higher contents at IS/FS compared with those at ES, indicating that the optimal harvest period of FCI should be at IS/FS. FCI extract could effectively suppress nitric oxide (NO) production in LPS-induced RAW264.7 cells and regulate the abnormal levels of cytokines and PGE2 in carrageenan-induced paw edema model rat. The results of quantitatively analysis revealed that the variation trends of phenolic acids and flavonoids in FCIs were different during flowering development, but most of them had higher contents at IS/FS than those at ES in all FCIs collected from eight cultivated regions, except one sample from Anhui. Finally, linarin, luteolin, apigenin and 3,5-dicaffeoylquinic acid were selected as the Q-markers based on the contribution of their AUC values in ROC and clustering of PCA analysis.
CONCLUSIONS: Our study demonstrates the optimal harvest period of FCI and specifies the multi-constituents Q-markers of FCI based on the influence of growth progression on the active constituents using untargeted/targeted metabolomics. The findings not only greatly increase the utilization rate of FCI resources and improve quality control of FCI products, but also offer new strategy to identify the Q-markers of FCI.
Procedure for obtaining a concentrated preparation of antihemophilic factor. Consist of: 1. Obtain a crioprecipitado of fresh plasma frozen by shredding of the blocks and fast defrost by constant agitation through a container with shirt by circulating water at 30gc. Crioprecipitado is purified at a temperature of 0.5 to 1ºc with tris-clh tampons. 2. Extraction of factor viii with tris-clh tampons at a temperature of 14 to 25 gc; the tampon/crioprecipitated proportion is 1.5 to 1 mm tampon per gram of initial cryoprepection; the extraction time is 15 to 60 minutes. 3. Stabilization of factor viii solution with 0.5 m sodium citrate until reaching 0.1 m. (Machine-translation by Google Translate, not legally binding)
Following a brief period of physical and cognitive rest (typically1-7 days, depending on symptom severity and timing of spontaneous symptom abatement), the physician advises participants to increase their activity levels gradually with minimal head movement (predominantly involving a stationary bike) and progressively increase levels of exertion while remaining under the threshold of symptom exacerbation. Subsequently, exercise progressed to include a progression of head movements, visual and cognitive burdens, sport-specific activities, and heavy resistance, in that order, all below the symptom exacerbation threshold.
PURPOSE:To provide an acidic beauty wash having skin beautifying effect, preservable for a long period, and resistant to clouding and denaturation, by adding an organic acid such as citric acid, lactic acid, malic acid, etc. to the juice of the fruit of a Cucurbitaceae plant or juice exudated from the stalk of the plant. CONSTITUTION:Juice of the fruits of Cucurbitaceae plant such as dishcloth gourd, cucumber, etc. or juice exudated from the stalk of the plant, is added with an organic acid such as citric acid, lactic acid, malic acid to obtain a wealky acidic beauty wash, pref. a beauty wash having a pH of about 3.0- 7.0. For example, juice exudated from the stalk of discloth gourd (89.7%), sorbit solution (10.0%), citric acid (0.2%), and sodium dehydroacetate (0.1%) are throughly mixed together to obtain a homogeneous mixture.
PURPOSE:To obtain a cosmetic base having excellent affinity for hair and skin, providing a nice feeling in use and a finishing feeling by using a specific low- viscosity cationic starch. CONSTITUTION:A low-viscosity cationic starch obtained by reacting a starch with a compound of formula I or formula II (R1 to R3 are 1-3C alkyl; X<-> is monovalent anion; Hal is halogen) in such a way that the content of nitrogen is 0.2-3wt.% is used as a cosmetic base. Namely the low-viscosity cationic starch is a low-viscosity cationic cosmetic having structure wherein the hydroxyl group of the starch is replaced with residue of formula III, 0.2-3wt.% of nitrogen content and 3-500cps viscosity in 30wt.% aqueous solution at 30 deg.C. The amount of the cosmetic base blended is preferably 0.1-7wt.%. This cosmetic base has excellent affinity for hair and skin, excellent film-forming ability and adsorbability to hair and skin. The cosmetic base has excellent moisture retention, makes hair wet, provides hair with stiff softness and luster and shows durability.
This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
PURPOSE: Cis-substituted aminocyclopropane derivatives are provided which have a wide antibacterial activity, especially strong antibacterial activities against gram-positive bacteria, particularly against quinolone-resistant bacteria, and capable of exhibiting good safety and actions in bodies. CONSTITUTION: A compound of formula I {each of R1, R2 are independently H, 1-6C alkyl; (n) is an integer of 1-3; Q is a group of formula II £R3 is a 1-6C alkyl, a 2-6C alkenyl, etc.; R4 is H, a 1-6C alkylthio; R5 is H, amino, hydroxyl group, etc.; X1 is halogen or H; A is N atom, a group of formula III (X2 is H, amino, a halogen, etc.); Y is H, phenyl, acetoxymethyl, etc.|, but the two substituents existing on the cyclopropane ring are placed in a is-configuration}, its salt and their hydrates are described. The compound of formula I can be produced by various kinds of methods. Thereby, the compound of formula I can be used as a medicine for human bodies, animals and fishes, and further as an agricultural chemical and a food preservative.
PURPOSE: A hedera helix leaf extract or a compound separated from the same are provided to utilize as a medicinal composition for prevention and treatment of an infectious diseas by an influenza virus or a health functional food by checking a high survival rate when taken together with an antivirus agent. CONSTITUTION: A medicinal composition for prevention and treatment of an infectious disease caused by an influenza virus contains a Hedera helix leaf extract or hederacoside C separated from the same as an active ingredient. The Hedera helix leaft extract is a crude extract, a polar solvent soluble extract, and a non-polar solvent soluble extract. The medicinal moposition for prevention and treatment of an infectious disease contains the combination of the Hedera helix leaf extract or hederacoside C and an anti-influenza agent. The anti-influenza agent is selected from Oseltamivir (Tamiflu), Zanamivir (Relenza), Peramivir, Amantadine (Symmetrel), Rimantadine, Rivaririn, or Taribavirin. [Reference numerals] (AA) Survival rate; (BB) Medicine injection; (CC) Time (day) after infection; (DD) Extract of Ivy leaf
Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
Disclosed are clear sprayable liquid antiperspirant compositions having viscosities of less than about 15 centistokes, comprising: an antiperspirant salt which is soluble, and which will remain soluble, in a monohydric alcohol solvent; high levels (30 % or greater) of emollient esters and silicone materials, having viscosities of from about 0.65 centistokes to about 50 centistokes, and solubility parameters of from about 4 to about 10; a surfactant solubilizer which is selected from the group consisting of ethoxylated or propoxylated nonionic surfactants having an HLB of from about 5 to about 18, and mixtures thereof, such that the average HLB of the solubilizer is from about 8 to about 14; and relatively low levels (less than about 50 %) of a monohydric alcohol solvent: wherein the antiperspirant compositions comprise no more than about 5 % water. These antiperspirant compositions provide excellent antiperspirancy and cosmetic in-use properties. They are non-sticky, non-greasy, and quick drying. They stain clothing less than other spray-on liquid antiperspirants. These compositions go onto the skin as a clear spray and leave no white, chalky, residue on skin upon dry down. These antiperspirant compositions also remain stable over time and a broad range of physical conditions, especially ambient temperatures.
Methylphenidate (MPH) has been previously shown to increase resting energy expenditure (REE) in individuals of normal weight; however, the effects on individuals living with obesity are currently unknown. Ten individuals living with obesity were randomly assigned to undergo 60 days of MPH administration with a daily dose of 0.5 mg/kg body weight or a placebo control. REE was measured before and after the 60-day intervention. There was a trend toward significance for group × time interaction on REE (p = 0.082) with a large effect size (η2 = 0.331), with MPH administration increasing REE compared to a decrease in placebo control. Preliminary findings from this pilot study show that MPH has the potential to counter the adaptive thermogenic process commonly seen in weight loss. This is a unique finding among pharmacotherapies, as no approved obesity drugs measurably impact REE.
Burn and scald are acute injury diseases caused when heat acts on human bodies, and at normal times or wartime, burn and scald are normally caused by flame and hot liquids. Generally the skin is damaged, and muscles and bones can be also injured. The local symptoms include erythema, swelling, blister, eschar, muscular death, tendon shrinkage and the like. When severe injury is caused, organ lesion can be caused as the fire heat and toxicity invade into viscera, and thus the life can be imperiled. The burn and scald medicine is a Chinese medicine preparation for treating burn and scald and comprises 6 Chinese medicines such as snapweed tuber, alums and borneol and the like according to a certain ratio. The medicine is externally used, namely, a wound surface is rubbed with, wetly covered with or soaked into the medicine till the wound is healed. The medicine has the functions of clearing away heat and toxic materials, purging pathogenic fire, promoting blood circulation to remove blood stasis, relieving swelling and pain, absorbing moisture, restraining the wound surface, moistening the skin and preventing infection, and has remarkable curative effects when being used for treating burn and scald. If the medicine is used for a long time, the purpose of heal can be completely achieved, and no sequela is caused.
Subjects will be provided extensive educational and ongoing support on the KD, including personalized coaching with the ability to text a dietitian at any time and expect a response within 12 hours. Diet adherence and progress will be assessed daily using at-home whole capillary blood ketone/glucose monitors, along with diet records. We will assess adherence based on days in ketosis following these parameters: (BHB ≥ 0.5mM). Adherence will be defined as \> 80% of days in ketosis.